AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.845

-0.035-1.86%

Volume:3.53M

Turnover:6.61M

Market Cap:2.36B

PE:-12.89

High:1.905

Open:1.880

Low:1.845

Close:1.880

Loading ...

Overview Company News Filings

Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value

Simply Wall St.

Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says

MT Newswires Live

Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?

Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler

Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%

MT Newswires Live

5 ASX All Ords shares upgraded to 'strong buy' consensus ratings

BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares

Mesoblast Ltd Files Prospectus Relates to Offer and Sale From Time to Time by the Shareholders of up to 34.7 Mln Ordinary Shares

THOMSON REUTERS

ASX Market Close: Miners lead bourse higher | February 5, 2025

The Market Herald

Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today

High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others

Simply Wall St.

Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?

3 ASX All Ords stocks smashing the benchmark this week

ASX Market Update: Real Estate & mining stocks lead index to another all-time high | January 31, 2025

The Market Herald

Mesoblast Plans Ryoncil Launch in March Quarter

MT Newswires Live

Why Lendlease, Mesoblast, St Barbara, and Zip shares are pushing higher

Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?

$1,000 invested in Mesoblast shares at the start of 2024 is now worth…

Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?

3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.845,"timestamp":1746166320000,"preClose":1.88,"halted":0,"volume":3531023,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":784338594,"shares":1277239284,"eps":-0.14313217499224326,"marketStatus":"Market Closed","change":-0.035,"latestTime":"05-02 16:12:00 AEST","open":1.88,"high":1.905,"low":1.845,"amount":6605433,"amplitude":0.031915,"askPrice":1.855,"askSize":10000,"bidPrice":1.845,"bidSize":3849,"shortable":3,"etf":0,"ttmEps":-0.14313217499224326,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1746403200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":1.88,"openAndCloseTimeList":[[1746144000000,1746165600000]],"volumeRatio":0.7330209700160539,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":784338594,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.138289,"volumeRatio":0.7330209700160539,"shares":1277239284,"dividePrice":0,"high":1.905,"amplitude":0.031915,"preClose":1.88,"low":1.845,"week52Low":0.88,"pbRate":"3.29","psRate":"267.90","week52High":3.37,"institutionHeld":0,"latestPrice":1.845,"committee":-0.444148,"eps":-0.14313217499224326,"divideRate":0,"volume":3531023,"delay":0,"ttmEps":-0.14313217499224326,"open":1.88,"prevYearClose":3.1,"prevWeekClose":1.79,"prevMonthClose":1.795,"prevQuarterClose":1.96,"fiveDayClose":1.79,"twentyDayClose":1.935,"sixtyDayClose":3.19},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510342445","title":"Domino's Pizza Enterprises And 2 Other ASX Stocks That Might Be Trading Below Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2510342445","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510342445?lang=en_us&edition=fundamental","pubTime":"2025-02-12 16:02","pubTimestamp":1739347352,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown positive momentum, with the ASX200 closing up 0.6% at 8,535 points, driven by strong performances in the Industrials and Financials sectors. As investors navigate these shifting landscapes, identifying undervalued stocks like Domino's Pizza Enterprises and others could offer potential opportunities for those seeking value in a buoyant yet selective market environment.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Domino's Pizza Enterprises is trading at A$33.35, significantly below its estimated fair value of A$53.18, indicating potential undervaluation based on cash flows. Although revenue growth is modest at 3.8% annually, earnings are expected to grow significantly by 24.1% per year over the next three years, outpacing the broader Australian market's growth rate of 12.3%. However, a high debt level and an unsustainable dividend coverage may pose challenges despite strong profit forecasts and a high future return on equity of 26.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dominos-pizza-enterprises-2-other-080232676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DPZ","DMP.AU","BK4532","BK4209","BK4139","BK4585","NCK.AU","MSB.AU","MESO","BK4524","BK4588"],"gpt_icon":0},{"id":"2510694533","title":"Cynata Therapeutics' Drug Candidate Could See Pricing Revision Following Mesoblast's Ryoncil Launch, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2510694533","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510694533?lang=en_us&edition=fundamental","pubTime":"2025-02-12 07:11","pubTimestamp":1739315479,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  lead asset, CYP-001, could see an upward revision in its pricing assumptions if the launch of Mesoblast's  Ryoncil sets a high market precedent, according to a Feb.10 note by Euroz Hartleys.Based on estimates, Ryoncil could be priced between $500,000 and over US$1 million per patient.Given that Ryoncil is the first US Food and Drug Administration-approved mesenchymal stem cell  therapy, its pricing may influence similar treatments, including CYP-001, Euroz added.Euroz Hartleys notes that while CYP-001, is unlikely to match Ryoncil's pricing, a price of $1 million per patient for Ryoncil could prompt an upward revision of CYP-001's current price estimate of $150,000 per patient.It maintained CYP's speculative buy rating and $0.67 price target.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","MSC","MESO","BK4150","CYP.AU","BK4139","LENZ","BK4575","MSB.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2510332542","title":"Is Mesoblast Limited (MESO) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332542","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510332542?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:56","pubTimestamp":1739292998,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Mesoblast Limited  stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight labor market is expected to keep RBA from initiating rate cuts until Q2 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-best-long-165638920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","SQQQ","TQQQ","LU0757428866.USD","TSYW.SI","MNQmain","NVIW.SI","NQmain","QID","RBA","LU1815336091.USD","MESO","MSB.AU","QLD","USAW.SI",".IXIC","LU1303367103.USD","PSQ","BK4139","BK4137","LU2098885051.SGD"],"gpt_icon":1},{"id":"2509420507","title":"Mesoblast Price Target Raised to $24.00/Share From $15.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2509420507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509420507?lang=en_us&edition=fundamental","pubTime":"2025-02-07 23:01","pubTimestamp":1738940460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 07, 2025 10:01 ET (15:01 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2509786731","title":"Mesoblast's Largest Shareholder Raises Stake to Over 19%; Mesoblast Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509786731","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509786731?lang=en_us&edition=fundamental","pubTime":"2025-02-07 08:07","pubTimestamp":1738886843,"startTime":"0","endTime":"0","summary":"Mesoblast's (ASX:MSB) largest shareholder Gregory George and G to the Fourth Investments raised their stake in the company to 19.13% from 18.10%, according to a Friday filing with the Australian bourse.The company's shares were up 3% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4141","BK7067","MMAT","XAO.AU","XKO.AU","BK7508","XJO.AU","BK4139","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2509929746","title":"5 ASX All Ords shares upgraded to 'strong buy' consensus ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=2509929746","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509929746?lang=en_us&edition=fundamental","pubTime":"2025-02-06 12:02","pubTimestamp":1738814543,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ords (ASX: XAO) shares are up 1.04% during a great day for the Aussie share market.  The All Ords enjoyed strong momentum in January, with the index lifting an impressive 4.38%. Here are f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/06/5-asx-all-ords-shares-upgraded-to-strong-buy-consensus-ratings/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MSC","BK7067","BK7083","ASK.AU","REIT","BK7501","BK4150","BK7511","BK4575","XAO.AU","BK7151","CHN.AU","REIT.AU","BK7508","BOE.AU","CSL.AU","MSB.AU","BK7095"],"gpt_icon":0},{"id":"2509725981","title":"BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509725981","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509725981?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:04","pubTimestamp":1738789479,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Ltd Files Prospectus Relates To Offer And Sale Of Up To 34.7 Million Ordinary SharesFeb 5  - Mesoblast Ltd MSB.AX:MESOBLAST LTD FILES PROSPECTUS RELATES TO OFFER AND SALE FROM TIME TO TIME BY THE SHAREHOLDERS OF UP TO 34.7 MILLION ORDINARY SHARESSource text: [ID:n0001213900-25-010524]Further company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW21S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK4139","BK7501","MSB.AU","MESO"],"gpt_icon":0},{"id":"2509256086","title":"Mesoblast Ltd Files Prospectus Relates to Offer and Sale From Time to Time by the Shareholders of up to 34.7 Mln Ordinary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2509256086","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509256086?lang=en_us&edition=fundamental","pubTime":"2025-02-06 05:03","pubTimestamp":1738789397,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW21S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","MSB.AU","BK4139","BK7508","MESO"],"gpt_icon":0},{"id":"2509421477","title":"ASX Market Close: Miners lead bourse higher | February 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509421477","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509421477?lang=en_us&edition=fundamental","pubTime":"2025-02-05 14:05","pubTimestamp":1738735500,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 0.51% at 8,416 points.The local market rose in response to China’s measured response to Trump’s tariffs.Materials was the best performing sector, up 1.6%, followed by IT, up 1.55%, and Energy, up 1.5%. Health Care was the biggest loser, down 0.55%.Insignia  closed up 6.9% after Brookfield Asset Management offered $4.60 a share in cash, matching current offers from Bain Capital and CC Capital Partners – and was also given limited due diligence.Woodside  closed up 1.7% as Brent Crude Oil climbed to around US$76 per barrel.Coronado Global Resources  closed up 1.5% after paring gains in morning trade. Most Aussie coal miners rallied after China’s retaliatory step to place tariffs on a basket of commodities then set expectations for higher prices.Mesoblast  closed down 5.3% despite no news today. It’s likely some investors are taking profits after the stock achieved strong gains over the last twelve months.Strickland Metals  finished down 2.7% after reporting results fr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-miners-lead-bourse-higher-february-5-2025-2025-02-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["CRN.AU","BK7047","BK7129","BK7062","BK7508","WDS.AU","BK7104","CWY.AU","IFL.AU","BK7067","STK.AU","BK7142","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2509244514","title":"Why Block, Canyon, Fisher & Paykel Healthcare, and Mesoblast shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2509244514","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509244514?lang=en_us&edition=fundamental","pubTime":"2025-02-05 10:02","pubTimestamp":1738720974,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on form and having a good session on Wednesday. In afternoon trade, the benchmark index is up 0.65% to 8,429 points. Four ASX shares that have failed to follow the m","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/05/why-block-canyon-fisher-paykel-healthcare-and-mesoblast-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7007","XJO.AU","FPH.AU","HCSG","MESO","MSB.AU","BK7158","BK7104","BK7508","CAY.AU","XYZ.AU","BK7501","BK4137","BK4139","BK7067"],"gpt_icon":0},{"id":"2508079521","title":"High Growth Tech Stocks in Australia Featuring FINEOS Corporation Holdings and Two Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2508079521","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508079521?lang=en_us&edition=fundamental","pubTime":"2025-02-04 12:02","pubTimestamp":1738641767,"startTime":"0","endTime":"0","summary":"The Australian market has recently shown signs of recovery, with the ASX200 rising by 0.5% to reach 8,430 points, and the IT sector leading gains at 1.6%. In this context of renewed optimism and sectoral strength, high growth tech stocks like FINEOS Corporation Holdings offer intriguing opportunities for investors seeking exposure to innovative companies in a rebounding market environment.Take a closer look at FINEOS Corporation Holdings' potential here in our health report.Understand FINEOS Corporation Holdings' track record by examining our Past report.Operations: Mesoblast Limited generates revenue primarily from the development of its cell technology platform, amounting to $5.90 million. The company operates within the regenerative medicine sector across multiple countries, including Australia and the United States.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-australia-040247051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7016","BK7501","MSB.AU","XAO.AU","FCL.AU","MESO","BK7503","PPS.AU","BK7067","BK7508","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2507952610","title":"Is Mesoblast Limited (MESO) One of the Best ASX Stocks to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507952610","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507952610?lang=en_us&edition=fundamental","pubTime":"2025-01-31 20:32","pubTimestamp":1738326722,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds.In this article, we are going to take a look at where Mesoblast Limited  stands against other best ASX stocks to buy according to hedge funds.According to a report by the Australian Bureau of Statistics  published on December 4, 2024, the Australian economy grew by 0.3% in the September quarter of 2024, which marked the twelfth consecutive quarter of growth. This growth, however, was the lowest rate since the December quarter of 2020 after the COVID-19 pandemic. The report also noted that in nominal terms, GDP rose by 0.4%.In terms of trade, a key indicator of the economy’s international competitiveness fell by 2.5% in the quarter. This decline was primarily due to a 2.6% drop in export prices and was the third consecutive quarterly fall. The weakening in global bulk commodity demand, particularly from China, significantly affected the prices of metallurgical coal and iron ore. Import prices also fell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mesoblast-limited-meso-one-best-123202290.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0225283273.USD","LU0106831901.USD","LU2089283258.USD","USJW.SI","LU1162221912.USD","BK7501","SQQQ","LU0912757837.SGD","TQQQ","LU0795875086.SGD","XAO.AU","BK4127","TSYW.SI","LU0267386448.USD","MNQmain","NVIW.SI","BK4516","NQmain","LU1074936037.SGD","LU2133065610.SGD","LU1989772840.SGD","QID","BK7067","LU0971096721.USD","MESO","IE00BZ1G4Q59.USD","BK4504","LU1989772923.USD","MSB.AU","LU1668664300.SGD","LU0314104364.USD","XJO.AU","LU0158827948.USD","LU1732800096.USD","QLD","LU0098860793.USD","USAW.SI",".IXIC","BK4534","LU2111349929.HKD","IE00BKVL7J92.USD","XKO.AU","LU0795875169.SGD","LU0158827781.USD","PSQ","LU2347655156.SGD","LU1548497426.USD","IBD","LU1732799900.SGD"],"gpt_icon":1},{"id":"2507451987","title":"3 ASX All Ords stocks smashing the benchmark this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2507451987","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507451987?lang=en_us&edition=fundamental","pubTime":"2025-01-31 12:12","pubTimestamp":1738296732,"startTime":"0","endTime":"0","summary":"The All Ordinaries Index is up 1.4% over the Australia Day holiday-shortened trading week, with three ASX All Ords stocks doing more than their share of the heavy lifting. One provides data solutions and services for machine learning and artificial intelligence . The second is an Australian gaming technology company. And the third outperforming ASX All Ords stock on my list is a clinical-stage biotechnology company. Which high-flying stocks am I talking about?Three ASX All Ords stocks roaring higher The first ASX All Ords stock to deliver shareholders outsized gains this week is Mesoblast Ltd . Shares in the company, which specialises in allogeneic cellular medicines to treat inflammatory diseases, closed last Friday trading for $2.87. At the time of writing today, shares are changing hands for $3.12 apiece, up 10.6%. That brings the Mesoblast share price gains over the past year to…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/31/3-asx-all-ords-stocks-smashing-the-benchmark-this-week/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7503","BK7067","BK7501","BK7508","APX.AU","ALL.AU","BK7061","MSB.AU","XAO.AU","BK7078"],"gpt_icon":0},{"id":"2507818549","title":"ASX Market Update: Real Estate & mining stocks lead index to another all-time high | January 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2507818549","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507818549?lang=en_us&edition=fundamental","pubTime":"2025-01-31 10:56","pubTimestamp":1738292160,"startTime":"0","endTime":"0","summary":"The ASX200 has hit yet another all-time high of 8,566 points in morning trade.The record was driven by a strong lead from Wall Street as well as buoyant mining and real estate stocks.Real Estate was the best performing sector, up 1.3%, followed by Materials, up 1.1%, and IT, up 0.85%. Utilities was the poorest performer, down 2.8%, followed by Telecommunication, down 0.25%.Mesoblast  has been up 2.3% on news of the U.S. launch of Ryoncil for pediatric graft-versus-host disease. The company says the focus is on finalising logistics and approvals to make the product available this quarter.Origin Energyhas been down 4.6% after revising its 2025 LNG production forecast. The company’s LNG revenue for the December 2024 quarter rose 3% from the previous quarter, reaching $2.71 billion, driven by higher LNG volumes and prices.PYC Therapeutics has been down 1.2% after to the next stage of its escalating single-dose study using its drug to treat a genetic children’s disease causing blindness.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-real-estate-mining-stocks-lead-index-to-another-all-time-high-january-31-2025-2025-01-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","MSB.AU","BK7130","BK7006","BK7067","PYC.AU","BK7501","BK7507","ORG.AU"],"gpt_icon":0},{"id":"2507986695","title":"Mesoblast Plans Ryoncil Launch in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2507986695","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507986695?lang=en_us&edition=fundamental","pubTime":"2025-01-31 10:26","pubTimestamp":1738290363,"startTime":"0","endTime":"0","summary":"Mesoblast  is set to launch its Ryoncil mesenchymal stromal cell therapy in the US during the first quarter for pediatric patients two months and older with steroid-refractory acute graft-versus-host disease, according to a Friday Australian bourse filing.The therapy was approved by the US Food and Drug Administration in December 2024. The firm is now awaiting national drug codes from the regulator, which will allow for the publication of product pricing in the US price compendia.The firm's commercial inventory has been manufactured and a distribution network has been established using specialty pharmaceutical services and distribution firm Cencora.Its commercial launch strategy will initially target centers with experience using the therapy at high volume, followed by a broader staged rollout.The firm has been working on finalizing product availability, including logistics, regulatory documentation, and contractual arrangements ahead of the launch, its chief executive Silviu Itescu sa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK4139","MSB.AU","BK7067","MESO"],"gpt_icon":0},{"id":"2507898875","title":"Why Lendlease, Mesoblast, St Barbara, and Zip shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2507898875","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507898875?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:10","pubTimestamp":1738285801,"startTime":"0","endTime":"0","summary":"In early afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on track to end the week with a solid gain. At the time of writing, the benchmark index is up 0.5% to 8,538.5 points. Four ASX shares that ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/31/why-lendlease-mesoblast-st-barbara-and-zip-shares-are-pushing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["MESO","BK7104","SBM.AU","BK7508","BK7506","MSB.AU","ZIP.AU","XJO.AU","LLC.AU","BK7501","BK7093","BK7067","BK4139","BK7121"],"gpt_icon":0},{"id":"2507998983","title":"Up 1,090% in a year, why is the Mesoblast share price leaping higher again on Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507998983","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507998983?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:04","pubTimestamp":1738285492,"startTime":"0","endTime":"0","summary":"Commenting on the results sending the Mesoblast share price higher again today, CEO Silviu Itescu said, \"We are committed to making our FDA-approved product Ryoncil available as quickly as possible to the many children with SR-aGVHD in need of life-saving therapy.\" Itescu added:  The team has been working relentlessly on finalising product availability, including logistics, regulatory documentation, and contractual arrangements to ensure a successful launch of Ryoncil this quarter.  On the financing front, Itescu said:  The successful financing of US$160 million this month, which provides the company with proforma cash on hand of approximately US$200 million, puts us in a strong position to execute the US commercial launch activities of Ryoncil, to expand the clinical indications of the product, and ensure that commercial manufacturing will meet projected product uptake and demand.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/31/up-1090-in-a-year-why-is-the-mesoblast-share-price-leaping-higher-again-on-friday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4575","BK7067","MESO","MSC","XKO.AU","MSB.AU","BK7501","BK7508","BK4150","BK4139"],"gpt_icon":0},{"id":"2507577603","title":"$1,000 invested in Mesoblast shares at the start of 2024 is now worth…","url":"https://stock-news.laohu8.com/highlight/detail?id=2507577603","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507577603?lang=en_us&edition=fundamental","pubTime":"2025-01-31 05:08","pubTimestamp":1738271293,"startTime":"0","endTime":"0","summary":"Let's dig a little deeper into things. Why did its shares rocket?Bell Potter still sees scope for Mesoblast's shares to keep rising. Its analysts recently put a speculative buy rating and $3.90 price target on them. It said:  The approval of Ryoncil has been transformational for the company with an exciting pipeline of products to follow. We retain our Buy  rating with valuation increased to $3.90  owing largely to the de-riskin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/31/1000-invested-in-mesoblast-shares-at-the-start-of-2024-is-now-worth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4575","BK4139","MSB.AU","MSC","BK7508","BK7067","BK7501","BK4150","MESO"],"gpt_icon":0},{"id":"2506374775","title":"Why Mesoblast (MESO) Is Among the Best Australian Stocks to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506374775","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506374775?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:03","pubTimestamp":1737983016,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Australian Stocks to Buy Now.In this article, we are going to take a look at where Mesoblast Limited  stands against other best Australian stocks to buy now.According to a report by Vanguard published on January 24, Australia’s economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024. The report forecasts an economic growth of 2% year over year by the end of 2025, with trimmed mean inflation, a core measure that excludes items at the extremes, expected to reach 2.5% year over year. However, the report notes that low productivity growth and higher unit labor costs will keep core inflation from falling sustainably to the midpoint of the Reserve Bank of Australia’s  2%–3% target range until later in 2025.Why do we care about what hedge funds do?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-mesoblast-meso-among-best-130336424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IBD","USJW.SI","XAO.AU","MSB.AU","BK7067","BK4137","BK4139","USAW.SI","XKO.AU","QLD","RBA","NVIW.SI","SQQQ","PSQ","TSYW.SI","NQmain","QID","MNQmain","LU0757428866.USD","MESO","BK7501","BK7104","XJO.AU","LU2098885051.SGD","LU1303367103.USD","TQQQ","LU1815336091.USD","BK7508",".IXIC","TAM.AU"],"gpt_icon":1},{"id":"2505011420","title":"3 ASX Growth Stocks With High Insider Ownership Seeing Up To 55% Earnings Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2505011420","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505011420?lang=en_us&edition=fundamental","pubTime":"2025-01-24 12:01","pubTimestamp":1737691293,"startTime":"0","endTime":"0","summary":"As the ASX200 experiences its third consecutive weekly gain, buoyed by a softer US stance on tariffs and calls for lower oil prices and interest rates, investors are keenly observing sectors like Discretionary and Real Estate that have shown robust performance. In this favorable environment, growth companies with substantial insider ownership can offer unique insights into potential earnings expansion, as insiders' vested interests often align closely with shareholder value creation.Top 10 Growth Companies With High Insider Ownership In Australia. Click here to see the full list of 91 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.Aussie Broadband is experiencing significant earnings growth, projected at 23.2% annually, outpacing the broader Australian market. Despite a slower revenue growth forecast of 8.6%, it remains above the market average. Recent insider activity shows more buying than selling, although no substantial purchases occurred in the pas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-growth-stocks-high-040133112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["MESO","MSB.AU","ABB.AU","EMR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":4,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}